EichorEICHOR
Condition: Advanced Solid Neoplasms Synced from ClinicalTrials.gov · August 03, 2026

Recruiting studies: Advanced Solid Neoplasms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PAS-004 in Patients With Advanced Solid Tumors
Phase 1 · 7 location(s) · Pasithea Therapeutics Corp. · NCT06299839A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06349811SKB445 for Injection in Solid Tumors
Phase 1 · 1 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT06826040A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral On
Phase 1 · 9 location(s) · Kestrel Therapeutics, Inc. · NCT07458347AMT-116 in Patients with Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Multitude Therapeutics Inc. · NCT06782334ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Phase 1 · 5 location(s) · Changchun Intellicrown Pharmaceutical Co. LTD · NCT04412616A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
Phase 1 · 6 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT06487455Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
NA · 7 location(s) · Institut Bergonié · NCT02534649A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE
EARLY_Phase 1 · 1 location(s) · Peking University · NCT06380309An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli
Phase 1 · 29 location(s) · BeOne Medicines · NCT07222267A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793A Study of ASP1002 in Adults for Treatment of Solid Tumors
Phase 1 · 15 location(s) · Astellas Pharma Global Development, Inc. · NCT05719558Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Phase 1 · 1 location(s) · Williams Cancer Foundation · NCT05544240Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Phase 2/Phase 3 · 4 location(s) · Intra-IMMUSG Pte Ltd · NCT07290088Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Phase N/A · 8 location(s) · Elephas · NCT07327489MAQ-001 in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · MabQuest SA · NCT06514651DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 35 location(s) · DynamiCure Biotechnology · NCT05785754Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06346041EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
Phase 1 · 2 location(s) · Peking University · NCT06541639An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-P
EARLY_Phase 1 · 1 location(s) · Celest Therapeutics (Shanghai) Co., Ltd. · NCT07680257A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Stingray Therapeutics · NCT06063681Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Phase 1/Phase 2 · 27 location(s) · Allist Pharmaceuticals, Inc. · NCT05288205A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injectio
Phase 1 · 65 location(s) · GlaxoSmithKline · NCT06431594A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 24 location(s) · DualityBio Inc. · NCT05785741A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT05740956A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or
Phase 1/Phase 2 · 1 location(s) · AP Biosciences Inc. · NCT05473156Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Phase 1/Phase 2 · 1 location(s) · Shanghai Public Health Clinical Center · NCT03093688A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Phase 1 · 4 location(s) · Aptamer Sciences, Inc. · NCT06687941Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and So
Phase 1 · 1 location(s) · Lantern Pharma Inc. · NCT06132503Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.